Pharmaceuticals Company Reports Positive Results For ED Study

Petros Pharmaceuticals has shared positive outcomes from a crucial Phase 2-equivalent study for STENDRA(R) (avanafil), marking a significant milestone in the medication's journey towards over-the-counter (OTC) availability. This innovative study paves the way for enhancing accessibility to treatment options for erectile dysfunction (ED), potentially transforming the therapeutic landscape. $Petros Pharmaceuticals(PTPI.US)$